Norwood Immunology - Phase II Clinical Trial - Melanoma Cancer Vaccine; First Patient Injected.MELBOURNE, Australia -- Norwood Abbey Limited (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). :NABYF) (ASX ASX See: Australian Stock Exchange :NAL NAL National Agricultural Library (Agricultural Research Service; US Department of Agriculture) NAL New American Library NAL National Accelerator Laboratory NAL National Aerospace Laboratory (Japan) ) today announced that its subsidiary, Norwood Immunology Limited (AIM:NIM nim 1 tr. & intr.v. nimmed, nim·ming, nims Archaic To steal; pilfer. [Middle English nimen, to take, from Old English niman; see ), a company focussed on the rejuvenation of the immune system, commenced its Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II . This is being undertaken in collaboration with The University of Texas M D Anderson Cancer Center, of Houston, under the supervision of Dr. Patrick Hwu, Professor and Chair of Melanoma Medical Oncology. This follows the Company's previous announcement of the signing of the trial agreement in October 2005. The first of the 100 patients (50 treated; 50 control) have been enrolled and the first patient has now been injected with Lupron Depot(R). This Phase II clinical trial is being undertaken to determine if there is an enhanced immune response to an investigational melanoma cancer vaccine, as a result of using the Company's technology as an adjuvant therapy. The trial is being funded by NIM with support from its US licence partner, TAP Pharmaceutical Products Inc, who market Lupron Depot(R) in the USA and certain grants applied for by Dr Hwu, the Principal Investigator. Richard Williams, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Norwood Immunology, commented: "I am please that we are now underway with this important trial and am appreciative of the assistance that we have had from Dr Hwu and his team at M D Anderson in achieving this important first milestone so quickly." Background: Norwood Immunology has licensed its immunology intellectual property to TAP Pharmaceutical Products Inc. for commercialization in the United States, utilizing TAP's GnRH analogue, Lupron Depot(R) (leuprolide acetate for depot suspension). This combined initiative is exploring the use of Lupron Depot in regenerating the thymus gland and in turn "re-booting" the body's immune system, enabling patients to better recover from life-threatening diseases. For further information on Norwood Abbey visit www.norwoodabbey.com. TAP Pharmaceutical Products Inc., located in Lake Forest, IL., U.S.A., is a joint venture between Abbott Laboratories, headquartered in Abbott Park, IL., U.S.A., and Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (武田薬品工業株式会社 Limited of Osaka, Japan. TAP currently markets Lupron Depot and Prevacid(R) (lansoprazole). For more information about TAP and its products, please visit the company's web site at www.tap.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion